MDACC Study No:2008-0267 ( NCT No: NCT00905034)
Title:Phase II study of methotrexate, vincristine, pegylated L-asparaginase and dexamethasone (MOAD) in acute lymphoblastic leukemia (ALL) salvage and Chronic Myeloid Leukemia (CML) in blast phase
Principal Investigator:Gautam Borthakur
Treatment Agent:Dexamethasone; Methotrexate; PEG-L-Asparaginase; Rituximab; Vincristine
Study Status:Terminated
Study Description:This goal of this clinical research study is to learn if the combination of
methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also
rituximab in some patients) can help to control ALL that has not responded to
previous treatment or has come back after a response or CML.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Dexamethasone
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:not applicable
Supported By:Sigma-Tau Pharmaceuticals, Inc.
Return Visit:minimum of one time a week for the first two weeks; 1-3 months thereafter.
Home Care:Treatment beyond first two weeks can be received by local oncologist.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults